Kantonsspital St.Gallen

Gerjan de Bruin

Kontakt

Gerjan de Bruin

Publikationen (7)

Xin B, Groll M, van der Marel G, Driessen C, Florea B, Kisselev A, Weyburne E, Janssens M, Du Y, Espinal C, Maurits E, Heinemeyer W, de Bruin G, Huber E, Overkleeft H. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits. J Med Chem 2019; 62:1626-1642.

Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.

de Bruin G, Xin B, Kraus M, van der Stelt M, van der Marel G, Kisselev A, Driessen C, Florea B, Overkleeft H. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. Angew Chem Int Ed Engl 2015; 55:4199-203.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.

Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.

de Bruin G, Groll M, van der Marel G, van der Stelt M, Driessen C, Kisselev A, Kim K, Al-Ayed K, van Rooden E, Xin B, Huber E, Overkleeft H. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem 2014; 57:6197-209.

Geurink P, Overkleeft H, Groll M, van der Stelt M, Driessen C, van der Marel G, Florea B, Mock E, Voges M, Blom A, de Bruin G, Gallastegui N, Mirabella A, van der Linden W, Kisselev A. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem 2013; 56:1262-75.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen Rorschacher Strasse 95 CH-9007 St.Gallen T: +41 71 494 11 11 support.forschung@kssg.ch